149 related articles for article (PubMed ID: 20517174)
1. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).
Watanabe T; Sakuyama K; Sasaki T; Ishii Y; Ishikawa M; Hirasawa N; Hiratsuka M
Pharmacogenet Genomics; 2010 Jul; 20(7):459-62. PubMed ID: 20517174
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether.
Honda M; Muroi Y; Tamaki Y; Saigusa D; Suzuki N; Tomioka Y; Matsubara Y; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2011 Oct; 39(10):1860-5. PubMed ID: 21746968
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of cytochrome P450 2B6 allelic variants.
Jinno H; Tanaka-Kagawa T; Ohno A; Makino Y; Matsushima E; Hanioka N; Ando M
Drug Metab Dispos; 2003 Apr; 31(4):398-403. PubMed ID: 12642465
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
[TBL] [Abstract][Full Text] [Related]
5. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
Bumpus NN; Sridar C; Kent UM; Hollenberg PF
Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
[TBL] [Abstract][Full Text] [Related]
6. Equine cytochrome P450 2B6--genomic identification, expression and functional characterization with ketamine.
Peters LM; Demmel S; Pusch G; Buters JT; Thormann W; Zielinski J; Leeb T; Mevissen M; Schmitz A
Toxicol Appl Pharmacol; 2013 Jan; 266(1):101-8. PubMed ID: 23142468
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
9. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling.
Spatzenegger M; Liu H; Wang Q; Debarber A; Koop DR; Halpert JR
J Pharmacol Exp Ther; 2003 Jan; 304(1):477-87. PubMed ID: 12490624
[TBL] [Abstract][Full Text] [Related]
10. Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.
Chang TK; Crespi CL; Waxman DJ
Methods Mol Biol; 2006; 320():97-102. PubMed ID: 16719378
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
[TBL] [Abstract][Full Text] [Related]
12. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Rohrbacher M; Kirchhof A; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer.
Kumagai J; Fujimura T; Takahashi S; Urano T; Ogushi T; Horie-Inoue K; Ouchi Y; Kitamura T; Muramatsu M; Blumberg B; Inoue S
Prostate; 2007 Jul; 67(10):1029-37. PubMed ID: 17455229
[TBL] [Abstract][Full Text] [Related]
14. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
[TBL] [Abstract][Full Text] [Related]
15. Bioactivation of chlorpyrifos by CYP2B6 variants.
Crane AL; Klein K; Olson JR
Xenobiotica; 2012 Dec; 42(12):1255-62. PubMed ID: 22775490
[TBL] [Abstract][Full Text] [Related]
16. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
Gadel S; Crafford A; Regina K; Kharasch ED
Drug Metab Dispos; 2013 Apr; 41(4):709-13. PubMed ID: 23298862
[TBL] [Abstract][Full Text] [Related]
17. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Xu C; Ogburn ET; Guo Y; Desta Z
Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
[TBL] [Abstract][Full Text] [Related]
18. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.
Ariyoshi N; Ohara M; Kaneko M; Afuso S; Kumamoto T; Nakamura H; Ishii I; Ishikawa T; Kitada M
Drug Metab Dispos; 2011 Nov; 39(11):2045-8. PubMed ID: 21821736
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Rotger M; Tegude H; Colombo S; Cavassini M; Furrer H; Décosterd L; Blievernicht J; Saussele T; Günthard HF; Schwab M; Eichelbaum M; Telenti A; Zanger UM
Clin Pharmacol Ther; 2007 Apr; 81(4):557-66. PubMed ID: 17235330
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles.
Restrepo JG; Martínez C; García-Agúndez A; Gaviria E; Laguna JJ; García-Martín E; Agúndez JA
Pharmacogenet Genomics; 2011 Dec; 21(12):773-8. PubMed ID: 21886015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
